ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Effect of SGLT2 inhibitors on atrial fibrillation recurrence after catheter ablation in patients with type 2 diabetes in the United States: a TriNetX database study.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is a common cardiac arrhythmia associated with significant morbidity and mortality, particularly in patients with type 2 diabetes mellitus (T2DM). Catheter ablation is a key treatment for AF, but recurrence rates remain high. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), used for glycemic control in T2DM, have shown potential in reducing arrhythmias. This study investigates the effect of SGLT2i on AF recurrence after catheter ablation in T2DM patients.
methodsWe conducted a retrospective cohort study TriNetX US Collaborative Network, identifying adults aged 18–80 years with type 2 diabetes mellitus (T2DM) who underwent catheter ablation for atrial fibrillation (AF) between 2013 and 2024. Patients were grouped by prior use of SGLT2 inhibitors. Propensity score matching (PSM) was applied on 66 covariates to balance baseline demographics, comorbidities, medications, laboratory values, and echocardiographic parameters. Outcomes included redo AF ablation, additional atrial ablation lines, electrical cardioversion, and anti-arrhythmic use.
resultsAfter PSM, 6,180 matched pairs were analyzed. SGLT2 inhibitor use was associated with a lower redo AF ablation rate (8.8% vs. 12.7%; RR 1.44, p < 0.001), fewer additional ablation procedures (4.6% vs. 5.7%, p = 0.021), and reduced anti-arrhythmic drug use (57.2% vs. 65.2%, p < 0.001). No significant difference was seen in electrical cardioversion rates.
conclusionAmong T2DM patients undergoing AF ablation, SGLT2 inhibitor therapy was linked to reduced need for repeat ablation, fewer complex ablation procedures, and decreased reliance on anti-arrhythmic medications, suggesting a potential rhythm-stabilizing benefit.
Indexed as
Identifiers
41134438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.